The estimated Net Worth of Linda M Rubinstein is at least $43.5 Tisíc dollars as of 7 June 2023. Linda Rubinstein owns over 100,000 units of Biocept Inc stock worth over $43,490 and over the last 3 years Linda sold BIOC stock worth over $0.
Linda has made over 1 trades of the Biocept Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Linda bought 100,000 units of BIOC stock worth $145,000 on 7 June 2023.
The largest trade Linda's ever made was buying 100,000 units of Biocept Inc stock on 7 June 2023 worth over $145,000. On average, Linda trades about 16,667 units every 0 days since 2021. As of 7 June 2023 Linda still owns at least 100,000 units of Biocept Inc stock.
You can see the complete history of Linda Rubinstein stock trades at the bottom of the page.
Linda's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY, CA, 94063.
Over the last 11 years, insiders at Biocept Inc have traded over $2,456 worth of Biocept Inc stock and bought 1,703,300 units worth $1,869,312 . The most active insiders traders include Claire Reiss, Edward A. Neff a David F Hale. On average, Biocept Inc executives and independent directors trade stock every 92 days with the average trade being worth of $27,462. The most recent stock trade was executed by David F Hale on 9 December 2021, trading 445 units of BIOC stock currently worth $1,807.
biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar
Biocept Inc executives and other stock owners filed with the SEC include: